Chapter 17: Hematopoietic Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

Today feels a little different.

The vibe is different.

Usually we're exploring these massive sprawling topics with articles from all over the internet, but today the lights are dim, the coffee is brewing, and we are laser focused.

It does feel a bit like a bunker in here or a library at 2 .00 a .m.

Exactly.

We are calling this the last minute lecture.

I'm picturing you, our listener, right now.

Maybe you're a med student, maybe nursing, maybe pharmacy.

You have an exam on hematopoietic drugs in let's say 48 hours.

The textbook is staring at you, conting you.

And that textbook is Brenner and Stevens Pharmacology sixth edition.

We're talking specifically chapter 17.

Right.

So here's the deal.

We aren't going to Google anything.

We aren't going to look up the latest experimental trials in Japan.

Nope.

We are sticking strictly to the four corners of chapter 17.

Our mission is to take this dense, dry material and turn it into a conversation that actually sticks in your brain so you can walk into that exam and crush it.

I like it.

A high yield study session.

We are going to decode the agents that build blood.

Hematopoietic.

It's a mouthful.

I always just think of it as blood making.

Well, that is literally what it translates to.

Himeido is blood.

Poesis is creation.

But before we even get to the drugs, we have to respect the system.

Yeah.

I mean, the sheer scale of what your bone marrow does every single day is,

it's just mind blowing.

The text mentions it's a It is a factory that never ever sleeps.

Your blood cells, red cells, white cells, platelets, they aren't immortal.

They have an expiration date.

But the marrow is constantly churning out billions of new cells to replace the ones that die.

And when they die, where do they go?

Do they just dissolve?

Not exactly.

They get taken out by the cleanup crew.

The text calls them the reticulo endothelial cells.

Okay.

Mostly in the liver and the spleen.

They identify the old beat up cells, engulf them and recycle their parts.

It's a constant cycle.

Creation in the marrow, destruction in the spleen.

Okay, so if the factory is working, we're good.

Yeah.

But the chapter focuses on when the factory fails, the problem state.

And the biggest headline here is anemia.

Right.

And for the purposes of this exam, and you know, for clinical practice, you need to understand why the anemia is happening.

It's not just one thing.

No, not at all.

The text breaks it down into three main buckets.

One, the factory is broken or doesn't have materials.

That's what they call inadequate erythropoiesis.

Okay.

Two, you're losing inventory, so blood loss.

Or three, the destruction rate is just too high.

That's accelerated hemolysis.

And today we are mostly focusing on that first bucket, the missing materials.

If you don't have the bricks, you can't build the house.

Exactly.

And there are three main nutritional bricks that the text highlights over and over again.

Iron, folic acid, and vitamin B12.

Right.

If you are missing any one of these, the assembly line just stops or it starts producing these weird defective cells.

Let's start with the heavy lifter.

Iron.

I feel like everyone knows iron is good for blood, but looking at figure 17 .1 in the book, the metabolism of iron is incredibly complex.

It seems like the body is actually almost terrified of iron.

That is a great observation.

The body should be terrified of iron.

It's essential.

It sits right in the center of the hemoglobin molecule and holds onto oxygen.

But free iron.

Yeah.

Free iron is toxic.

It causes oxidative stress.

It basically rusts you from the inside out.

So the body has this very, very elaborate system to keep it on lockdown.

So let's trace the path.

I eat a steak or some spinach.

There's iron in it.

What happens next?

You swallow it, but here is the first hurdle.

The text says the average diet has about 18 to 20 milligrams of iron a day.

Okay.

Sounds like a lot.

It does, but we only absorb about 10 % of that.

Wait, only 10 %?

That seems incredibly inefficient.

We poop out 90 % of the iron we eat.

We do.

And that's actually a safety mechanism.

The body refuses to take in more than it needs because unlike other minerals, we don't have a good way to excrete excess iron.

Once it's in, it's really hard to get out.

So the main gatekeeper is the gut.

But the text mentions a regulatory loophole, something about when stores are low.

Yes.

So if your stores are low, say you're bleeding or you're pregnant, the gut gets the signal to open the gates.

Absorption can increase two or even threefold.

It's a smart system.

Okay.

So the iron gets past the gut wall.

It's in the bloodstream.

It can't just float around, right?

Because of that toxicity issue you mentioned.

Correct.

It needs chaperone.

Immediately, it hops onto a transport protein called transferrin.

I always visualize transferrin as an armored truck.

That's perfect.

That's a great way to think about it.

It's an armored truck that shuttles the iron safely through the circulation.

And where does the truck go?

Mostly to the erythroid marrow, the factory, to be put into new red blood cells.

But if there is extra, it goes to the liver for storage.

And when it's stored, it changes its name again.

This is where I always get mixed up on tests.

Transferrin versus ferritin.

Super common point of confusion.

Here's an easy way to remember.

Transferrin transfers.

Transfers.

Got it.

Ferritin is the storage halt.

When you look at a patient's labs, the ferritin level tells you how much iron is locked away in the warehouse.

Okay.

That clicks.

So transferrin moves it, ferritin keeps it.

Now eventually, that iron ends up in a red blood cell.

It circulates for, what is it?

About 120 days.

That's the average lifespan of a red blood cell.

And then the spleen eats it.

Does the iron get flushed out with it?

No.

And this is the conservative part the text talks about.

The body recycles that iron.

The scavenger cells rip the hemoglobin apart, take the iron, and load it right back onto the transferrin truck to go back to the marrow.

Wow.

It's an incredibly tight, efficient loop.

Very little is lost.

Which begs the question.

If the system is so good at recycling, why do so many people get iron deficiency anemia?

Because the demand can outstrip the supply.

Think about infants and pregnant women.

The text highlights them as the highest risk groups for a reason.

Because they're growing, building new stuff.

Exactly.

A fetus is aggressively building its own blood supply, and it's stealing iron directly from the mother.

If the mother's dietary intake can't keep up, and remember she can only ramp up absorption so much, she goes into debt.

Let's talk about that debt.

The text describes a sequence of events.

You don't just wake up anemic one day, it's a slow crash.

It's a staged failure, absolutely.

Stage one, you raid the savings account.

The body pulls iron out of ferritin storage in the liver.

At this point, your blood accounts look totally normal, but your vault is emptying.

And you wouldn't even know it.

You'd have no idea.

Then what?

Stage two, I'm guessing.

Stage two, the vault is empty.

Now,

the serum iron, the iron on the trucks, on the transferrin starts to drop.

The factory is running out of parts.

And finally.

Stage three.

The factory slows down production.

You start pumping out defective products, and this is the key for the exam.

You have to know this term,

hypochromic microcytic anemia.

Let's break those words down.

Hypochromic.

Hypo means low.

Chromic means color.

The cells are pale.

They look ghostly under a microscope because they don't have enough red hemoglobin packed inside.

And microcytic.

Small cells.

Micro for small.

The factory can't build them to full size, so they come out tiny.

If you see a low MCV that's mean corpuscular volume on a lab sheet, your brain should immediately scream iron deficiency.

Okay, so we've diagnosed it.

We have pale tiny cells.

The patient is tired.

We need to fix it.

Let's move to the drug section of the chapter.

Oral iron.

This is the standard of care.

The text lists a few different salts.

Ferrous sulfate, ferrous gluconate, and ferrous fumarate.

Why ferrous?

Why not ferric?

What's the difference?

The chemistry matters here.

Iron exists in two main states.

Ferrous, which is F2 plus 8, and ferric, which is F3 plus 8.

The gut is very, very picky.

Okay.

It absorbs the ferrous form much, much better.

So all our oral drugs are designed to deliver iron in that ferrous state.

Okay, so we give them a ferrous pill, but there is a huge catch regarding how they take it.

And it seems like a constant battle between pharmacokinetics and just patient comfort.

It is the classic dilemma.

Pharmacokinetically, you want to take iron on an empty stomach.

The text is crystal clear.

Food retards absorption by 40 to 60%.

That's huge.

If I take my iron with breakfast, I'm potentially losing more than half the dose.

Exactly.

But here's the problem.

Iron salts are harsh.

They really irritate the stomach lining.

They cause epigastric pain, nausea, cramping.

So the patient feels sick.

Right.

And if you tell a patient to take it on an empty stomach and it makes them feel sick every single time, what are they going to do?

Stop taking it.

They're going to stop taking it.

So compliance becomes the number one issue.

So what do we do?

What's the compromise?

We compromise.

The text says it's often necessary to administer iron with food just to ensure compliance.

Yes, you lose a big chunk of absorption, but a lower absorbed dose is infinitely better than zero dose.

That makes sense.

What about those sustained release pills, the ones that dissolve slowly?

That sounds like a smart way to avoid the stomach pain.

It sounds smart, but the text calls it out as a bad idea.

It's a physiological mismatch.

How so?

Iron is primarily absorbed in the duodenum, the very first section of the small intestine.

It's like there's a specific loading dock right there.

I see where this is going.

If the pill is sustained release, it's designed to dissolve slowly over hours.

It might not release its iron until it's past the duodenum.

So it misses the window.

It completely bypasses the only window of opportunity.

It travels down to the jejunum or ileum where absorption is terrible.

The pill essentially becomes useless.

So avoid sustained release,

stick to the standard salts.

How long does the treatment last?

A week?

A month?

No way!

Remember the empty vault, the empty ferritin stores?

Right.

You can fix the anemia itself, the hemoglobin in the blood in a few weeks, but you have to keep treating for three to six months to completely refill the ferritin stores in the liver.

Ah, so it's a longer term project.

It is.

If you stop too early, the patient has no reserves and they'll just relapse the next time they have some minor blood loss.

Let's talk side effects.

We mentioned the stomach pain, but there's one that always freaks patients out.

The black stools.

Yeah.

Iron turns your poop black and not just dark brown.

We're talking tarry jet black.

It looks exactly like melena, which is the medical term for digested blood from a GI bleed.

That's terrifying.

A patient would think they're bleeding internally.

They would.

So you have to warn them.

It's a critical piece of counseling.

You have to say this will happen.

It is harmless.

It means the iron is working.

Do not call 911.

And for the kids,

liquid iron.

It stains their teeth.

It can turn them a nasty gray black color.

The tip from the textbook is to have them drink it through a straw so it bypasses the teeth or to brush immediately after taking it.

Let's hit the safety check on drug interactions.

Iron seems like a bit of a diva.

It doesn't play well with others.

It really doesn't.

First off, it needs an acidic environment to be absorbed.

So if a patient is taking antacids or proton pump inhibitors like omeprazole for heartburn, their iron absorption crashes.

Which is ironic because the iron itself can give them heartburn.

So they want to take an antacid.

It's a vicious cycle.

Then you have certain antibiotics.

The text calls out tetracyclines and fluoroquinolones.

Iron binds to them in the gut.

It chelates them.

What does that mean for the patient?

It means if you take them together, you absorb neither the iron nor the antibiotic.

You fail to treat the anemia and you fail to treat the infection.

It's a total therapeutic failure.

So space them out by a few hours.

At least two hours apart.

Yeah.

Is there anything that actually helps absorption?

Vitamin C, ascorbic acid.

It acts as a reducing agent, keeping the iron in that sweet ferrous F2 plus state that the gut loves.

So telling a patient to take their iron with a glass of orange juice is actually evidence -based medicine.

Good tip.

Now one serious, serious warning from the text that we have to talk about.

Toxicity.

We cannot stress this enough.

Iron packaging is not childproof just for fun.

Acute iron toxicity in children is a medical emergency.

It can be lethal.

What does it do?

It causes necrotizing gastroenteritis.

It literally eats through the stomach and intestinal lining, which is then followed by shock, metabolic acidosis, and can lead to coma and death.

Keep these pills locked up and away from children.

Okay, that's oral iron.

But what if the patient can't tolerate it?

Or what if they have malabsorption issues from,

say, celiac disease or chronic kidney disease?

Then we have to bypass the gut entirely.

We go to parenteral iron, injectable.

The classic one listed is iron dextrin.

Right.

It's a mixture of ferric hydroxide and dextrin molecules.

But injecting iron is not without risk.

Anaphylaxis.

The body can have a severe, life -threatening allergic reaction to the dextrin part of the molecule.

The text notes that newer, low -molecular weight versions are much safer.

But the risk is still there.

You always give a small test dose first.

And there's a specific way to give it intramuscularly.

I am.

That sounds complicated.

The Z -Track technique.

This is a classic nursing exam question.

Iron dextrin is a dark brown liquid.

If you just stick a needle in the buttock and pull it out, the solution can leak back up the needle track into the subcutaneous fat and the skin.

Leaving a stain.

A permanent, dark brown, tattoo -like stain.

And it's inflammatory.

It's not just cosmetic.

So the Z -Track technique involves pulling the skin to the side, laterally displacing it before you inject.

Okay.

You push the needle in, inject the iron deep into the muscle, wait a few seconds, pull the needle out, and then you let the skin slide back into its normal position.

So the layers of tissue slide over each other and seal the hole.

Exactly.

It creates a Z pattern in the tissue layers, which traps the iron deep in the muscle where it belongs.

That is surprisingly mechanical.

Pull the skin to seal the hole.

Okay.

Before we leave iron, let's look at the case study in Box 17 .1.

It really brings all of this to life.

This is the story of a 25 -year -old journalist.

She comes in with the classic triad of symptoms.

Fatigue, weakness, restless legs.

But she also has a very specific, very weird symptom.

She likes to chew ice.

Pagophygia.

It's a specific type of pica.

Pica is the craving for non -food items, right?

Like clay or dirt or paper.

Right.

But specifically craving and chewing ice is almost pathognomonic for iron deficiency.

We don't really know why, but if a patient tells you they are chewing through three trays of ice a day, you need to check their iron.

So they check her labs.

What do they see?

It's a textbook case.

Hemoglobin is 10 .7.

That's low mild anemia.

Her transfer and saturation is only 8%.

Normal is usually 20, 50%.

Her ferritin is 10.

She's running on absolute fumes.

But her MCV.

Her MCV is 75.

Microsidic.

Small cells.

It fits the pattern perfectly.

The text says she has iron deficiency anemia caused by menorrhagia -heavy menstrual bleeding.

So how do they treat her?

They attacked it from both sides, which is smart.

First, stop the leak.

They put her on oral contraceptives to reduce the menstrual blood loss.

Second, fill the tank ferrous sulfate twice a day.

And did she have the side effects we talked about?

She did.

She got constipated.

The doctors prescribed psyllium fiber and plenty of water to manage it.

And crucially, they told her that if the stomach pain was too bad, she could take it with food.

There's that compromise again.

Compliance over perfection.

Exactly.

And the happy ending.

Tell me.

Six months later, her hemoglobin is up to 12.

Her ferritin is 22.

And the ice chewing completely stopped.

It's amazing how a simple mineral can have such a profound effect on someone's life.

All right.

Let's pivot.

We are leaving the small cell world.

We are entering the world of big cells.

The vitamins.

Folic acid and vitamin B12.

This is probably the most important distinction in the entire chapter, isn't it?

It is, without a doubt.

If you take one thing away, it's this.

Iron deficiency makes cells small or microcytic.

Folate or B12 deficiency makes cells huge.

Megaloblastic anemia or macrocytic anemia.

Why do they get so big?

That seems counterintuitive.

It's a failure of division.

Think about it.

The red blood cell precursors in the marrow, the erythroblasts, they grow and grow, getting ready to divide into two daughter cells.

OK.

But to divide, they need to duplicate their DNA.

Both folate and B12 are absolutely essential for DNA synthesis.

If you lack them, the cell can't copy its DNA, so it can't divide.

It just sits there getting bigger and bigger and eventually turns into this giant fragile blob that dies early.

A megaloblast.

That's the one.

Let's start with folic acid, also known as vitamin B9.

Folic acid is a donor.

Chemically, its job is to donate single carbon units.

It's like a brick layer handing over single bricks that are used to build amino acids and, more importantly, the bases for DNA purines and pyrimidines.

And who needs this the most?

Anyone who's making new cells rapidly.

But the critical population the text highlights is pregnant women.

We talked about this with iron, but the stakes here seem even higher.

They are.

If a developing fetus doesn't get enough folate in the first few weeks of pregnancy, the neural tube doesn't close properly.

This leads to devastating birth defects like spina bifida or encephaly.

And this happens so early, the woman might not even know she's pregnant yet.

That's the danger.

That's the whole reason for the public health recommendation that all women of childbearing age should take a folate supplement.

And it's why, as the text notes, the FDA mandated grain fortification back in 1998.

They started putting folic acid in bread, pasta, and cereal.

And did it work?

It was a massive public health success.

Neural tube defects in the US dropped by over 25%.

Just an incredible outcome.

That is incredible.

Now, can drugs cause this deficiency?

Yes, definitely.

If you have a patient on methotrexate, which is a powerful cancer and autoimmune drug, that drug works specifically by inhibiting the enzyme that activates folate, an enzyme called dihydrofolate reductase.

It's designed to starve cancer cells of folate, but it starves the healthy cells too.

Okay, let's move to the partnering crime, vitamin B12, also known as cobalamin.

This is a really complex molecule.

It has a porphyrin -like ring with a cobalt atom right in the middle, hence the name cobalamin.

And it has a very strange journey into the body.

It's not as simple as swallow and absorb.

No, not at all.

B12 is extremely high maintenance.

To be absorbed in the last part of the small intestine, the ileum, it absolutely must be bound to a protein called intrinsic factor.

Well, where does intrinsic factor come from?

It's secreted by the parietal cells of the stomach lining, the same cells that make stomach acid.

So if I have surgery that removes part of my stomach, like a gastrectomy, you lose the parietal cells.

You lose intrinsic factor.

You can eat all the B12 -rich steak you want, but you will not absorb it.

You will inevitably develop B12 deficiency.

And this specific condition has a name, right?

Pernicious anemia.

It's usually caused by an autoimmune process where the body's own immune system attacks and destroys those gastric parietal cells.

So for these patients, a B12 pill is useless?

Effectively, yes.

If the transport mechanism intrinsic factor is broken, oral pills don't work well unless you give them an absolutely massive doses.

The standard treatment is injection.

You bypass the gut completely.

Intramuscular B12, often for life.

Now, we need to slow down and talk about the trap.

The text has a giant warning sign around this, the relationship between folate and B12.

This is the folate trap.

It is the classic medical board trick question, and it's a tragedy if you miss it in real life.

It is critically important.

Walk us through it.

Vitamin B12 deficiency causes two major problems.

Number one, anemia, the megaloblastic kind we've been talking about.

And number two, neurological damage.

Nerve damage.

Yes.

Severe, potentially irreversible nerve damage.

B12 is needed to maintain the myelin sheath, the fatty insulation on your nerves.

Without it, you get tingling, numbness, balance issues, and eventually it can progress to permanent dementia or paralysis.

OK, that's really bad.

It is.

Now, here is the trap.

If you give folic acid to a B12 deficient patient, the folic acid will fix the anemia.

The blood cells will start dividing again.

The labs will look beautiful.

The hemoglobin will normalize.

So the doctor might think, great, problem solved.

Exactly.

But folic acid does nothing for the neurological damage.

It doesn't fix the myelin problem.

So while the doctor is celebrating the normal blood count, the patient's spinal cord is quietly degenerating.

Whoa.

So you're masking the most dangerous part of the disease.

You're silencing the warning sign while the house is burning down.

Perfectly put, that is why the text emphasizes.

You must rule out B12 deficiency before treating a megaloblastic anemia with folic acid.

If you have a patient with big cells, you have to check both levels.

That is high yield.

Do not mask the B12 deficiency with folate.

Before we leave B12, there is one cool emergency use mentioned in the chapter, cyanide poisoning.

Right.

The text mentions a drug called hydroxycobalamin.

Yeah.

So cyanide poisoning -like from smoke inhalation in a house fire is deadly fast.

It stops your cells from using oxygen.

Hydroxycobalamin is basically just a B12 precursor.

OK.

It has a high affinity for cyanide.

You inject it.

It finds the cyanide in the blood, binds to it, and turns into Don't tell me.

Cyanobalamin.

Which is just vitamin B12.

Which is just regular vitamin B12.

That is chemical jujitsu.

It turns a deadly poison into a daily vitamin.

It's one of the most elegant mechanisms in all of pharmacology.

Truly brilliant.

All right.

We've done the bricks, which was iron.

We've done the blueprints, the vitamins.

Now let's talk about the foreman, the managers,

the hematopoietic growth factors.

These are the signaling proteins, the cytokines that scream at the bone marrow.

Work harder or make more of the cell type.

First up, the red cell boosters, ESAs, erythropoiesis stimulating agents.

To understand these, you have to understand the kidney.

The kidney is the master oxygen sensor of the body.

When it senses low oxygen levels in the blood passing through it, it releases a hormone called erythropoietin, or EPO.

And ESAs are just synthetic versions of this hormone.

Exactly.

The first one developed was epoetin alpha.

It's basically identical to the human hormone made with recombinant DNA technology.

But then pharma got clever.

They started modifying it.

They wanted to improve the pharmacokinetics.

Epoetin alpha has a relatively short half -life, so it has to be injected frequently.

So they made darbapoetin alpha.

They added sugary polysaccharide chains to it.

Then they made methoxypolyethylene glycol epoetin beta.

They attached a long peg chain.

And what does all that extra stuff do to the molecule?

It acts like a shield.

It protects the molecule from being broken down and cleared by the body.

It extends the half -life significantly.

So instead of needing shots every few days, maybe you only need one every few rents.

What are these drugs for?

The biggest group by far is patients with chronic kidney disease, or CKD.

Their kidneys are failing.

They can't make their own natural EPO.

They are anemic because they lack the signal.

We provide that signal for them.

The text also mentions use in cancer chemotherapy and for some patients with HIV.

Yes, to counteract the bone marrow suppression caused by those powerful drugs.

But, and this is a big but, there's the dark side.

The chapter is very clear about the black box warnings.

This is a massive shift in medicine that's happened in the last 15 years or so.

We used to think, hey, let's use these drugs to get the hemoglobin back to normal.

Let's get everyone up to 14 GDL.

Seems logical.

More oxygen -carrying capacity has to be better.

It turned out to be deadly.

When you push the hemoglobin that high with these drugs, the blood gets thick.

It becomes more viscous, like trying to pump sludge through the arteries.

And sludge causes blockages.

Exactly.

Hypertension, stroke, myocardial infarction, the death rates went up in the clinical trials.

It was a huge shock.

So what is the rule now?

What's the goal of therapy?

The FDA pumped the brakes hard.

Now, the goal is not normal hemoglobin.

The goal is just enough.

We usually don't start treatment until hemoglobin is below 10.

And we aim to stop or reduce the dose once it hits 10 or 11.

Just enough to keep the patient from needing a blood transfusion.

That's it.

And for cancer patients, it's even worse.

Yeah.

There's some evidence that ESAs can actually act as growth factors for the tumor itself.

That some tumors have EPO receptors.

So you might actually be feeding the cancer.

They're used with extreme caution in that population.

We can't talk about EPO without mentioning the elephant in the room.

Doping in sports.

Lance Armstrong.

The text actually name drops him.

It's the most famous example of drug abuse in sports history, probably.

Cyclists used EPO to illegally boost their red cell count, carrying more oxygen to their muscles, giving them a huge endurance advantage.

But think about the risk we just discussed.

Vick of blood.

These elite athletes were riding bikes up mountains in the Tour de France with blood.

The consistency of yogurt.

It's a miracle more of them didn't drop dead from strokes right there on the road.

Wow.

There is one weird new drug in this section.

Luspattercept.

It's a maturation agent.

It's a different mechanism.

It works on late stage red blood cells that are kind of stuck in development and helps push them over the finish line to become mature erythrocytes.

Niche use.

Very niche.

The text says it's for beta thalassemia and mildest plastic syndromes.

But an interesting mechanism to know about.

All right.

Let's move to the white blood cells.

The neutrophil boosters.

Colony stimulating factors or CSFs.

Neutrophils are your foot soldiers.

They are your first line of defense against bacterial infections.

Chemotherapy absolutely nukes them.

When your neutrophil count drops to zero, you are a sitting duck for any infection.

So we give them filgrastem, GCSF, granulocyte colony stimulating factor.

It stimulates the marrow to specifically pump out neutrophils and fast.

And just like with EPO, we have a PEG version.

PEG filgrastem.

You used a great analogy in pre -show for pedulation.

The sumo suit.

Let's explain that.

Okay.

So the kidneys acts like a filter with tiny holes.

They filter out small proteins from the blood.

Filgrastem is a small protein.

It gets filtered and peed out pretty quickly.

So it has a short half -life.

Right.

But if you chemically attach a long chain of polyethylene glycol or PEG to it, you are basically putting the drug in a giant inflatable sumo suit.

It makes the molecule massive.

Huge.

It's now too bad to fit through the holes in the kidney filter.

It just bounces off and stays in the blood.

PEG filgrastem has a half -life of 42 hours compared to filgrastem's 3 .5 hours.

That is a total game changer for a chemo patient.

One shot per cycle instead of having to come in for daily jabs.

It's a huge quality of life difference.

Absolutely.

What's the downside?

If you force the marrow to work that hard and make that many white cells, does it?

Does it hurt?

It does.

Bone pain is the most common side effect.

Specifically in the lower back, the pelvis, the sternum, the areas with a lot of marrow.

The marrow is physically expanding inside the rigid bone.

It aches.

Section 7.

Platelets.

The forgotten child of hematopoiesis.

We need them to clot, to stop bleeding.

The natural hormone here is thrombopoietin, or TPO.

But we don't use a recombinant version of the hormone, right?

The text says we use agonists, the drugs that mimic it.

Correct.

The text lists romeplastum.

Which is a peptibody.

I love that word.

It sounds like something out of science fiction.

It's a fusion protein, part peptide, part antibody.

It's engineered to bind to the thrombopoietin receptor and wake it up, telling the marrow to make more platelets.

And L -trombopag.

That one is an oral small molecule.

The advantage here is obviously that it's a pill, not an injection.

These are used for a condition called ITP -immune thrombocytopenia, where the patient's own immune system is destroying their platelets.

Okay, we are in the homestretch.

Section 8.

The most distinct disease state in the chapter.

Sickle cell disease.

This is a genetic tragedy.

A single amino acid swap in the hemoglobin beta chain creates an abnormal hemoglobin called hemoglobin S.

And when oxygen is low.

The hemoglobin S molecules polymerize.

This is the key visualization for you to have.

The hemoglobin molecules link together inside the red blood cell to form long, stiff, rigid rods.

Like tent poles popping up inside a balloon.

That's a perfect analogy.

It stretches the cell from its nice flexible donut shape into that stiff crescent or sickle shape.

These cells are no longer flexible.

They get stuck in tiny capillaries.

A logjam.

It causes a logjam vaso occlusion.

No blood gets through.

The tissues downstream starve for oxygen.

It causes excruciating episodes of pain called pain crises.

The text lists four drugs.

And what I love is that they attack the problem from four totally different angles.

It's a masterclass in targeting a complex pathology.

Drug one, voxelotor.

This is the direct approach.

It binds directly to the hemoglobin S and physically stops the polymerization from happening.

It prevents the rods from forming in the first place.

It keeps the cell round and flexible.

Drug two, chrysanilizumab.

This is the Teflon approach.

It doesn't stop the sickling itself.

It targets a molecule called P -selectin.

P -selectin is a sticky molecule on the inside of blood vessel walls.

Sickled cells and other cells love to stick to it.

Chrysanilizumab is a monoclonal antibody that blocks P -selectin.

So even if the cells are sickle -shaped, they just slide right through.

They don't stick.

No logjam.

The goal here is to prevent the pain crises from happening.

Drug three, hydroxyurea.

The old guard.

This is actually a cancer drug, a ribonucleotide reductase inhibitor.

But in sickle cell, it does something magic.

It tells the bone marrow to switch back to making fetal hemoglobin, or HBF.

Why is fetal hemoglobin good?

Fetal hemoglobin doesn't have the beta chain with the mutation, so it doesn't sickle.

It effectively dilutes the bad hemoglobin S.

The text admits the exact mechanism is still a bit mysterious, but it increases HBF, increases cell water content, and reduces stickiness.

It's been a mainstay for decades.

And drug four, L -glutamine.

This is the antioxidant approach.

Sickled red blood cells are under massive oxidative stress, which makes them fragile.

L -glutamine is a precursor for glutathione, which is the body's main intracellular antioxidant.

It helps protect the cells and makes them more resilient.

Four drugs.

One stops the shape change.

One stops the sticking.

One changes the hemoglobin type.

And one protects against stress.

That's incredible.

It's amazing progress for a disease that had almost no specific options for a very long time.

Okay.

We have covered the map.

We've built the blood.

We've fixed the deficiencies.

We've boosted the counts.

And we've treated the sickle cells.

We have.

Now, listener, if you're driving, pull over the car.

Or pause the treadmill.

It's quiz time.

The text has review questions at the end of the chapter.

I'm going to read the scenario.

You try to answer in your head before.

Our expert speaks.

No pressure.

Question one.

A 19 -year -old woman complains of lethargy and fatigue.

Her labs show a hemoglobin of 9 .8, which is low.

Her MCV is low.

And her MCHC is low.

What drug do we give her?

Is it A, sanocobalamin, B, apoetin, C, ferrous fumarate, D, filgrastem, or E, folate acid?

Okay.

Identify the keywords.

Low hemoglobin means anemia.

Low MCV means mitrocytic.

Small pale cells.

What causes small pale cells?

Iron deficiency.

Iron deficiency.

Which drug on that list is iron?

C, ferrous fumarate.

Question two.

A 47 -year -old woman has severe neutropenia after a round of chemotherapy.

What drug accelerates the recovery of her neutrophils?

The key word is neutropenia.

Low neutrophils.

We need a colony stimulating factor to boost the white cells.

We need the GO signal for granulocytes.

That is D, filgrastem.

Question three.

A 66 -year -old man has progressive fatigue.

His hemoglobin is low, but his MCV is elevated, and his serum methylmalonic acid is elevated.

Okay.

Stop right there.

Elevated MCV means macrocytic.

Big cells.

So your brain should immediately go to either folate or B12 deficiency.

How do we distinguish between them?

The methylmalonic acid.

Remember, B12 is the cofactor needed to break down methylmalonyl CoA.

If you lack B12, that acid piles up in the blood.

Folate deficiency does not cause that.

So this is B12 deficiency.

The drug is A, cyanocobalamin.

And if we gave him folic acid instead?

We'd fix his blood count, but we would be frying his nerves.

The folate trap.

Question four.

A 68 -year -old man with end -stage renal disease presents with anemia and reticulocytopenia, which means no new cells are being made.

The key here is end -stage renal disease.

His kidneys are dead.

No kidneys means no natural erythropoids and signal.

We need to replace that hormone.

The answer is B, ipodin.

Last one.

Question five.

What is the purpose of pedulation of a protein drug like filgrostin?

Is it A, increasing oral bioavailability?

B, decreasing the renal excretion rate?

C, increasing the duration of action?

Or D, increasing binding to its receptors?

This is a slightly tricky one because two of the answers sound right.

Pedulation creates the sumo suit.

It prevents the kidney from filtering the drug out.

So the direct mechanism is B, decreasing the renal excretion rate.

Now, because the excretion rates decrease, the duration of action increases, which is answer C.

But B is the cause and C is the effect.

The primary pharmacologic change is the excretion rate.

Boom, five out of five.

We survived chapter 17.

So final thought, we've gone deep into this.

What is the one thing you want the student, our listener, to take away from this session?

It's that hematopoiesis is a system of finely tuned balance, and our drugs have to respect that balance.

You can't just throw these agents at a problem blindly.

If you give iron to someone who doesn't need it, you can poison them.

If you give folate to a B12 deficient patient, you mask an impending neurological disaster.

If you give too much EPO, you cause a stroke.

You have to understand the underlying deficiency before you treat.

Pharmacotherapy here is all about precision replacement.

Precision replacement, I like that.

All right, Lerner, you've done the work.

You listened to the mechanisms.

You know the traps.

Now go take that exam or see that patient and be the smartest person in the room.

You got this.

From the last minute lecture team, thanks for listening to the deep dive.

Good luck.